At Biogen, our mission is clear: we are pioneers in neuroscience. Since our founding in 1978 as one of the world’s first global biotechnology companies, Biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurological diseases.
We believe that no other disease area holds as much need or as much promise for medical breakthroughs as neuroscience. Our focus on neuroscience, our deep scientific expertise and our courage to take risks make us leaders in the research and development of medicines to transform neuroscience to benefit society.
We aspire to transform patients’ lives and Biogen by making personalized & digital medicine in neuroscience a reality. Powered by data science and digital technologies, we drive solutions to advance research, clinical care, and patient empowerment. We believe that now, more than ever, biology and technology should go hand-in-hand to better meet patient needs, while enabling a shift towards more prevention-focused, affordable, and equitable care.
We came to Biogen to solve the unsolvable. We stay to create new possibilities and grow together. We work fearlessly and go beyond because we care deeply about making a difference and changing lives. All legitimate correspondence from a Biogen employee will come from “@biogen.com” or “@smartrecruiters.com” email accounts.
Biogen’s science & manufacturing expertise enables production of biosimilars of advanced biologics
Biogen believes biosimilars are central to safeguarding future healthcare innovation. Biosimilars can alleviate some of the burden on healthcare systems by offering cost savings and promoting earlier and sustainable access to therapies. Biosimilars can also expand options for patients and physicians to meet individual needs. Biogen has the expertise to manufacture and reliably supply biosimilars.
WHAT ARE BIOSIMILARS?
Biosimilars are medicines that are highly similar to currently available biologic therapies, known as “reference medicines.” Having successfully delivered complex biologics for approximately 40 years, Biogen is one of only a handful of companies with the manufacturing capabilities and deep scientific expertise needed to produce biosimilars of advanced biologics.
Biogen’s portfolio of biosimilars medicines currently spans a number of indications across two distinct therapy areas; Ophthalmology and Immunology (also described as inflammatory disease).
ANTI-VEGF THERAPIES (OPHTHALMOLOGY)
Our portfolio (existing & pipeline) includes anti-VEGF (vascular endothelial growth factor) therapies, which are marketed in the US, and in future will be marketed in the European Union, as well as other major markets worldwide including Canada, Japan and Australia.
Anti-VEGF therapies treat retinal vascular disorders, which are a leading cause of blindness.
These include: neovascular (wet) age-related macular degeneration (AMD); visual impairment due to diabetic macular oedema (DME); proliferative diabetic retinopathy (PDR); visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO); visual impairment due to choroidal neovascularisation (CNV).
These therapies are biosimilars, referencing currently-available biologic products. By bringing biosimilars to a new therapeutic area, we are expanding treatment options with the goal of sustainably advancing broad, timely access to care for patients in need.
By applying our heritage of scientific innovation to clear medical needs, Biogen hopes to make a meaningful difference to the lives of the many patients we serve.
ANTI-TNF THERAPIES (IMMUNOLOGY)
Our portfolio of anti-TNF therapies is marketed in the European Union, where Biogen is a leading provider of these medicines.
Anti-TNF treatments reduce inflammation and may prevent disease progression by targeting an inflammation-causing substance called Tumor Necrosis Factor (or “TNF”).
TNF inhibitors are used to treat inflammatory conditions, such as rheumatoid arthritis, psoriatic arthritis, juvenile arthritis, inflammatory bowel disease (Crohn’s disease and ulcerative colitis), ankylosing spondylitis, and psoriasis.
There are an estimated 30 million patients in Europe today who are directly affected by these inflammatory conditions. Biosimilar therapies have the potential to significantly and sustainably expand patient access to life-changing biological medicines.
RESOURCES FOR HEALTHCARE PROFESSIONALS
At Biogen, our goal is to provide healthcare professionals with the information needed to support their clinical practice.
The below websites have been created for healthcare professionals based in the EU. They outline important information on our products, key clinical data, supporting materials and other valuable resources.
Biogen currently serves 247,000 patients affected by Immune Medicated Inflammatory Diseases (IMIDs) across Europe - in addition to a large network of clinicians. Through our educational and digital initiatives, we aim to provide healthcare professionals with meaningful clinical education to help them in their clinical practice.
The Biosimilars Medical Academy is an educational platform designed by medical professionals to provide high quality medical education. The Academy brings you exclusive content on biological treatments and educational resources for selected therapy areas, using engaging content developed with internationally renowned Key Medical Experts (KMEs).
If you are a healthcare professional based in the EU, click here to access the Biosimilars Medical Academy.
If you are a healthcare professional based in the United States, click here to access the Biosimilars Medical Academy.
You are now leaving Biogen’s corporate website.
Third Party Sites
Biogen assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site's endorsement of Biogen or this website.